Celltrion's YUFLYMA® Secures Full FDA Interchangeability for All Dosage Forms Celltrion announces FDA's expanded interchangeability designation for YUFLYMA® (adalimumab-aaty), a key development in biosimilar medications.

Celltrion's YUFLYMA® Secures Full FDA Interchangeability for All Dosage Forms #South_Korea #Incheon #Celltrion #Humira #YUFLYMA

Celltrion's YUFLYMA® Receives Expanded FDA Interchangeability Designation Celltrion, Inc. proudly announces that its biosimilar YUFLYMA® has received expanded FDA interchangeability designation for all its dosage forms, improving patient access.

Celltrion's YUFLYMA® Receives Expanded FDA Interchangeability Designation #None #Celltrion #Humira #YUFLYMA

Celltrion's YUFLYMA® Receives FDA's Interchangeable Designation to Humira® Celltrion’s YUFLYMA® has been recognized by the FDA as an interchangeable biosimilar to Humira®, enhancing access for patients across various treatment needs.

Celltrion's YUFLYMA® Receives FDA's Interchangeable Designation to Humira® #USA #Incheon #Celltrion #Humira #YUFLYMA